|Bid price||1,936.00||Open price||1,936.00|
|Ask price||1,938.00||Prev close||1,938.00|
Register now for FREE live Hikma Pharmaceuticals share prices, Hikma Pharmaceuticals stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Hikma Pharmaceuticals Level 2 Data, indepth research tools and investor commentary for Hikma Pharmaceuticals (HIK) and other London Stock Exchange equities.
Register now for FREE Hikma Pharmaceuticals share price charts
|Sector||Pharmaceuticals & Biotechnology||ISIN||GB00B0LCW083|
|Activites||Hima Pharmaceuticals plc is a multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products.||Index||FTSE 100|
|Latest Share Price (p)||1,938.00||Net Gearing (%)||26.65|
|Market Capitalisation (£m)||4,662.32||Gross Gearing (%)||47.94|
|Shares in issue (m)||239.95||Debt Ratio||32.57|
|P/E Ratio||15.35||Debt-to-Equity Ratio||0.52|
|Total dividends per share (p)||32.00||Assets / Equity Ratio||1.92|
|Dividend Yield (%)||1.06||Price to book value||3.45|
|Dividend cover (x)||3.19||ROCE (%)||15.86|
|Earning per share (p)||126.60||EPS Growth (%)||-9.83|
|52 week high / low||2,703.00 / 1,575.00||DPS Growth (%)||45.45|
|Dec.Date||Type||Director||Pos||No. of Shares|
Hikma Pharmaceuticals' wholly-owned US subsidiary, Roxane Laboratories, has received an approval for its generic equivalent to Xyrem from the US Food and Drug Administration. Roxane's Sodium Oxybate oral solution 500 mg/mL is indicated for the treatment of cataplexy (sudden loss of muscle...
RNS Number : 4587U Hikma Pharmaceuticals Plc 18 January 2017 Hikma receives approval for Sodium Oxybate Oral Solution London, 18 January 2017 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P,...
JP Morgan Cazenove today reaffirms its overweight investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and cut its price target to 2100p (from 2450p). Story provided by StockMarketWire.com
Register now for FREE Hikma Pharmaceuticals company news
Floated in London last November at 290p (FTSE-250). Company website www.hikma.com Develops, manufactures and markets branded and non-branded generic pharmaceuticals, as well as in-licensed, patented pharmaceuticals Geographic markets: USA, Europe and the Middle East & North Africa...
Register now for FREE Hikma Pharmaceuticals share price discussions